Cancer Biomarkers Market

Report Overview

The global cancer biomarkers market was pegged at US$ 12.2 in 2021 and is expected to witness a CAGR of 11.2% during the forecast period.

Market Fundamentals

A biomarker is a molecule found in body fluid, blood, and tissue, and is evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic treatment. A cancer biomarker refers to a biomarker that is indicative of the presence of cancer in the body. Biomarker testing used to find proteins, genes, and other substances that can provide information about cancer. Each person with cancer has a unique pattern of biomarkers, and cancer biomarker tests help the doctor select the best suitable cancer treatment. 

[765453434]

Market Dynamics

The global cancer biomarkers market is mainly driven by the prevalence of various types of cancers, increasing chronic diseases, increasing research and development activities, and increasing applications of biomarkers in cancer diagnostics and drug discovery. Furthermore, rising investments in screening cancer welfare, and growing demand for personalized medicine are other factors contributing to market growth. However, high cost involved in biomarker validation and stringent government regulations are likely to restrain market growth to a certain extent.

Market Ecosystem

The global cancer biomarkers market has been analyzed from five perspectives: Type, Profiling Technology, Application, Cancer Type, and Region.

Cancer Biomarkers Market by Type

[87654534]

Based on type, the cancer biomarkers market has been segmented into genomic biomarkers, proteomic biomarkers, transcriptomic biomarkers, and others (epigenomic biomarkers, metabolomic biomarkers, etc.). Genomic biomarkers are dominating the global cancer biomarkers with largest share owing to the technological advancements and widespread adoption of genetic biomarkers for early diagnosis of cancer owing to its greater speed and accuracy in detection. Additionally, new genome sequencing tests (Whole genome sequence, whole exome sequence, sanger sequence, and others), introduction of a genome sequencer platform, accuracy of cancer screening, and demand for personalized medicine are contributing to market growth.  In June 2022, Illumina launched TruSight oncology 500HRD Assay for next generation cancer screening. It is codeveloped with Merck on validated HRD technology from Myriad Genetics and analyzes more than 500 genes including those relevant to HRD status.

Cancer Biomarkers Market by Profiling Technology

Based on profiling technology, the global cancer biomarkers market has been segmented into omic technologies, imaging technologies, immunoassays, and others (cytogenetics, bioinformatics, etc.). Omic technologies dominated the market with the largest share in 2021. Omic technologies are high throughput techniques that enable the fast discovery of candidate biomarkers. It allows for gathering large amounts of data about human genome, proteins, and metabolites. This technology is expected to co-evolve with biomarker-based precision medicine leading to better patient care.

Cancer Biomarkers Market by Application

Based on application, the cancer biomarkers market has been segmented into diagnostics, drug discovery & development, personalized medicine, and others (disease risk assessment, prognostics, etc.). The diagnostics market is expected to be the fastest growing during the forecast period. The growth of the segment attributed to the rising demand for biomarker-based diagnostic, high specificity, accuracy, and less price of cancer screening as compared to biopsy. Additionally, affordable genome cancer screening, introduction new biomarker, and immune response screening are some of the factors that contributing growth of cancer biomarkers market.

Cancer Biomarkers Market by Cancer Type

Based on cancer type, the cancer biomarkers market has been segmented into breast cancer, prostate cancer, lung cancer, colorectal cancer, blood cancer, skin cancer, and others (cervical cancer, thyroid cancer, bladder cancer, kidney cancer, etc.). The breast cancer segment dominated the cancer biomarkers market attributed to prevalence of breast cancer, raising awareness about cancers, technological advancement in diagnosis, and government policies for cancer treatment. According to, The Breast Cancer Organization in March 2022, in the U.S. about 1 out of 8 women develop invasive breast cancer. Almost 287,850 new cases of invasive breast cancer cases are expected diagnose for invasive breast cancer and 51,400 non-invasive breast cancer.

Cancer Biomarkers Market by Region

Based on region, the global cancer biomarkers market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the cancer biomarkers market with the largest share in 2021, followed by the Asia Pacific. The large share of North America in the global market can be largely attributed to the growing prevalence of various types of cancer, increasing R&D activities associated with biomarkers, and greater adoption of biomarkers technologies in personalized medicine and drug discovery & development for the treatment of cancer.

Competitive Landscape

Some of the prominent players operating in the cancer biomarkers market are 

• Qiagen NV
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc
• General Electric Company
• Abbott Laboratories Inc
• Agilent Technologies, Inc
• Bio-Rad Laboratories, Inc
• Illumina, Inc
• bioMérieux SA
• Myriad Genetics, Inc
• Among others

Strategic Developments

• In May 2021, GE Healthcare acquired France-based in-vivo oncology and neurology biomarker developer Zionexa to further develop molecular imaging agents for cancer treatment
• In April 2021, BostonGene and the Medical College of Wisconsin announced a research partnership to identify predictive biomarkers for pancreatic cancer
• In February 2021, Crown Bioscience partnered with Cambridge Quantum Computing (CQC) on the identification of novel cancer treatment biomarkers. Under the terms of the deal, Crown Bioscience will combine its preclinical and translational research expertise and datasets with CQC's quantum machine algorithms and software development capabilities, to identify multi-gene biomarkers that can be used in cancer drug discovery
• In August 2020, GeneCentric Therapeutics announced a research collaboration with Janssen Research & Development, LLC (Janssen) on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC)
• In March 2020, Proteomedix announced the commercial launch of its blood-based test for prostate cancer diagnosis in Europe

Frequently Asked Questions About This Report